Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-11-25 |
2024-09 |
-0.17 |
N/A |
N/A |
N/A |
2024-08-06 |
2024-06 |
-0.15 |
-0.14 |
0.01 |
6.67% |
2024-05-09 |
2024-03 |
-0.13 |
-0.13 |
N/A |
N/A |
2024-02-07 |
2023-12 |
-0.15 |
-0.11 |
0.04 |
26.67% |
2023-11-27 |
2023-09 |
-0.16 |
-0.12 |
0.04 |
25.00% |
2023-08-08 |
2023-06 |
-0.17 |
-0.14 |
0.03 |
17.65% |
Date |
Firm |
Action |
From |
To |
2023-08-07 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-07-19 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-06-28 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-05-01 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2023-03-30 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2023-02-08 |
BTIG |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2021-06-28 |
BOENISCH SANDRA |
Officer and Treasurer |
22.96K |
Sale |
2024-06-13 |
DONHAUSER PETER D.O. |
Director |
5.00K |
Purchase |
2021-05-20 |
FAVUS ELLIOT J. M.D. |
Director |
0.00 |
Sale |
2012-05-28 |
LALACH HARVEY |
President |
550.00K |
Sale |
2024-03-27 |
MISSLING CHRISTOPHER U |
Chief Executive Officer |
1.25M |
Sale |
2022-05-24 |
SKARPELOS ATHANASIOS |
Director |
1.31M |
Sale |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Blackrock Inc. |
5.94M |
48.28M |
7.25% |
2023-06-29 |
State Street Corporation |
4.41M |
35.84M |
5.38% |
2023-06-29 |
Vanguard Group Inc |
4.20M |
34.18M |
5.13% |
2023-06-29 |
Geode Capital Management, LLC |
1.54M |
12.54M |
1.88% |
2023-06-29 |
Northern Trust Corporation |
735.99K |
5.98M |
0.90% |
2023-06-29 |
NWAM LLC |
634.60K |
5.16M |
0.77% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-08-30 |
SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF |
2.95M |
23.34M |
3.61% |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
2.27M |
18.43M |
2.77% |
2023-08-30 |
iShares Russell 2000 ETF |
1.61M |
12.72M |
1.96% |
2023-06-29 |
Vanguard Extended Market Index Fund |
1.10M |
8.94M |
1.34% |
2023-07-30 |
Fidelity Small Cap Index Fund |
628.31K |
5.18M |
0.77% |
2023-08-30 |
iShares Russell 2000 Growth ETF |
590.24K |
4.66M |
0.72% |
Split |
Date |
1 : 4 |
2015-10-07 |